Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H2 2016’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections

The report reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Influenza A Virus, H1N1 Subtype Infections therapeutics and enlists all their major and minor projects

The report assesses Influenza A Virus, H1N1 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Akshaya Bio Inc.

Altimmune, Inc.

Antigen Express, Inc.

Beijing Minhai Biotechnology Co., Ltd

CEL-SCI Corporation

Cilian AG

ContraFect Corporation

EpiVax, Inc.

Etubics Corporation

Gemmus Pharma Inc.

iBio, Inc.

ILiAD Biotechnologies, LLC

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Kineta, Inc.

Kyowa Hakko Kirin Co., Ltd.

Lakewood-Amedex Inc

Medicago Inc.

MedImmune, LLC

Microbiotix, Inc.

Mucosis B.V.

NanoViricides, Inc.

NewLink Genetics Corporation

OPKO Health, Inc.

PeptiDream Inc.

Recce Pty Ltd

Sarepta Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

TechnoVax, Inc.

Touchlight Genetics Limited

Vaccibody AS

Vaxart, Inc.

Vironova AB

Visterra, Inc.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Influenza A Virus, H1N1 Subtype Infections Overview 6

Therapeutics Development 7

Influenza A Virus, H1N1 Subtype Infections - Therapeutics under Development by Companies 9

Influenza A Virus, H1N1 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 12

Influenza A Virus, H1N1 Subtype Infections - Pipeline Products Glance 13

Influenza A Virus, H1N1 Subtype Infections - Products under Development by Companies 16

Influenza A Virus, H1N1 Subtype Infections - Products under Investigation by Universities/Institutes 20

Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development 21

Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment 57

Drug Profiles 67

Influenza A Virus, H1N1 Subtype Infections - Dormant Projects 164

Influenza A Virus, H1N1 Subtype Infections - Discontinued Products 168

Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones 169

Appendix 182

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2016 15

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Development by Companies, H2 2016 (Contd..3) 27

Products under Investigation by Universities/Institutes, H2 2016 28

Influenza A Virus, H1N1 Subtype Infections – Pipeline by AbbVie Inc, H2 2016 29

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Akshaya Bio Inc., H2 2016 30

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Altimmune, Inc., H2 2016 31

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Antigen Express, Inc., H2 2016 32

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 33

Influenza A Virus, H1N1 Subtype Infections – Pipeline by CEL-SCI Corporation, H2 2016 34

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cilian AG, H2 2016 35

Influenza A Virus, H1N1 Subtype Infections – Pipeline by ContraFect Corporation, H2 2016 36

Influenza A Virus, H1N1 Subtype Infections – Pipeline by EpiVax, Inc., H2 2016 37

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Etubics Corporation, H2 2016 38

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Gemmus Pharma Inc., H2 2016 39

Influenza A Virus, H1N1 Subtype Infections – Pipeline by iBio, Inc., H2 2016 40

Influenza A Virus, H1N1 Subtype Infections – Pipeline by ILiAD Biotechnologies, LLC, H2 2016 41

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 42

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Johnson & Johnson, H2 2016 43

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Kineta, Inc., H2 2016 44

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 45

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Lakewood-Amedex Inc, H2 2016 46

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Medicago Inc., H2 2016 47

Influenza A Virus, H1N1 Subtype Infections – Pipeline by MedImmune, LLC, H2 2016 48

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Microbiotix, Inc., H2 2016 49

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Mucosis B.V., H2 2016 50

Influenza A Virus, H1N1 Subtype Infections – Pipeline by NanoViricides, Inc., H2 2016 51

Influenza A Virus, H1N1 Subtype Infections – Pipeline by NewLink Genetics Corporation, H2 2016 52

Influenza A Virus, H1N1 Subtype Infections – Pipeline by OPKO Health, Inc., H2 2016 53

Influenza A Virus, H1N1 Subtype Infections – Pipeline by PeptiDream Inc., H2 2016 54

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Recce Pty Ltd, H2 2016 55

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Sarepta Therapeutics, Inc., H2 2016 56

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 57

Influenza A Virus, H1N1 Subtype Infections – Pipeline by TechnoVax, Inc., H2 2016 58

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Touchlight Genetics Limited, H2 2016 59

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Vaccibody AS, H2 2016 60

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Vaxart, Inc., H2 2016 61

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Vironova AB, H2 2016 62

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Visterra, Inc., H2 2016 63

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 64

Assessment by Monotherapy Products, H2 2016 65

Assessment by Combination Products, H2 2016 66

Number of Products by Stage and Target, H2 2016 68

Number of Products by Stage and Mechanism of Action, H2 2016 70

Number of Products by Stage and Route of Administration, H2 2016 72

Number of Products by Stage and Molecule Type, H2 2016 74

Influenza A Virus, H1N1 Subtype Infections – Dormant Projects, H2 2016 172

Influenza A Virus, H1N1 Subtype Infections – Dormant Projects (Contd..1), H2 2016 173

Influenza A Virus, H1N1 Subtype Infections – Dormant Projects (Contd..2), H2 2016 174

Influenza A Virus, H1N1 Subtype Infections – Dormant Projects (Contd..3), H2 2016 175

Influenza A Virus, H1N1 Subtype Infections – Discontinued Products, H2 2016 176

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2016 15

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 65

Assessment by Combination Products, H2 2016 66

Number of Products by Top 10 Targets, H2 2016 67

Number of Products by Stage and Top 10 Targets, H2 2016 67

Number of Products by Top 10 Mechanism of Actions, H2 2016 69

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 69

Number of Products by Routes of Administration, H2 2016 71

Number of Products by Stage and Routes of Administration, H2 2016 71

Number of Products by Top 10 Molecule Types, H2 2016 73

Number of Products by Stage and Top 10 Molecule Types, H2 2016 73

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports